Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by itntdfon Aug 24, 2023 5:20pm
228 Views
Post# 35604443

RE:RE:RE:exel panc phase 3 study stopped and unblinded early

RE:RE:RE:exel panc phase 3 study stopped and unblinded earlybelieve notable addressed part of your questions.  my point in posting this was to pony onto some of notable's recent posts addressing the pathway forward and the possibility of outstanding results in an area where there are few to none options for treatment that oncy could advance one of their fast tracks without the need to finish a phase 3.

we certainly have not lost the race and at any rate we were not in a race with exel.

on the downside, we won't have a registration trial until around the middle of 2024.  we could, however, have our pre-registration trial stopped with eye-opening results and maybe get that approval to market and move into a phase 4 bypassing some or all of a phase 3.

hope springs eternal but some of us don't have an eternity to wait.

results will move the needle and i don't mean murine results.
<< Previous
Bullboard Posts
Next >>